---
layout: default
title: Pegvisomant
parent: 僅模型預測 (L5)
nav_order: 258
evidence_level: L5
indication_count: 10
---

# Pegvisomant
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

Using the report template above (no additional skill applies — this is a direct content-generation task from the given Evidence Pack), here is the report:

---

# Pegvisomant: From Original Indication (Data Unavailable) to Borderline Ovarian Serous Tumor

## One-Sentence Summary

> Pegvisomant (DrugBank DB00082) currently has no confirmed original indication or mechanism-of-action data in this evidence pack — both are flagged as data gaps.
> The TxGNN model predicts it may be effective for **Borderline Ovarian Serous Tumor**,
> but this prediction is currently supported by **0 clinical trials** and **0 publications**, and the drug holds **no EU/Taiwan marketing authorization**.

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not available — original indication and MOA are documented data gaps (DG002) |
| Predicted New Indication | Borderline Ovarian Serous Tumor |
| TxGNN Prediction Score | 98.63% |
| Evidence Level | L5 |
| EU Market Status | Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |

## Why is This Prediction Reasonable?

Detailed mechanism of action data is not currently available for Pegvisomant in this evidence pack (data gap DG002), and no approved original indication is on record here (the drug holds zero EU/Taiwan marketing authorizations). This significantly limits how confidently the predicted new indication can be evaluated against the drug's established pharmacology.

The rationale generated for the top-ranked prediction states that the GH–IGF-1 signaling axis is upregulated in some ovarian tumors, and that theoretically blocking this axis could inhibit cell proliferation. However, this is explicitly noted as a speculative mechanistic hypothesis with **no direct evidence** supporting Pegvisomant's use in borderline ovarian serous tumor — a condition that is managed surgically, not through GH-receptor antagonism.

A notable pattern across the top 10 predictions deserves caution: **8 of the 10** predicted indications are ovarian tumor entities (mostly benign cystadenomas/papillomas), while the remaining two (pyelonephritis, an infection, and aleukemic mast cell leukemia, a KIT-driven malignancy) have no plausible mechanistic link to GH-receptor antagonism at all. This concentration pattern, combined with rationale notes on ranks 8 and 10 explicitly flagging possible "embedding-space clustering" effects, suggests the predictions may partly reflect structural proximity of ovarian-disease nodes in the knowledge graph rather than an independently validated pharmacological signal. This should be reviewed at the graph level before further investment in this candidate.

## Clinical Trial Evidence

Currently no related clinical trials registered.

## Literature Evidence

Currently no related literature available.

## EU Market Information

Pegvisomant currently holds **no marketing authorization** in the available EU/Taiwan regulatory dataset (market status: Not Marketed; total authorizations: 0). No license records are available to summarize dosage form or approved indication text.

## Safety Considerations

Please refer to the SmPC for safety information.

Note: the underlying label warnings and contraindications data (DG001) are marked as a **Blocking** data gap in this evidence pack, meaning safety cannot currently be formally assessed (S1 stage) for this candidate — this alone is sufficient to prevent progression regardless of the prediction score.

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The predicted indication is supported only by the TxGNN model score (Evidence Level L5) with zero clinical trials or publications, the drug has no EU/Taiwan marketing authorization, and — most critically — the safety data gap (DG001, Blocking severity) prevents any formal safety evaluation from proceeding. The strong clustering of 8/10 predictions around ovarian tumor entities also raises a data-quality concern that should be resolved before this signal is treated as biologically meaningful.

**To proceed, the following is needed:**
- TFDA/EMA product label (SmPC) with warnings and contraindications (resolves DG001, Blocking)
- Confirmed mechanism of action via DrugBank API (resolves DG002)
- Confirmation of Pegvisomant's actual approved indication(s) in relevant jurisdictions
- Preclinical/mechanistic studies on GH–IGF-1 axis relevance in ovarian tumor biology
- Graph-level review of the TxGNN embedding to rule out node-clustering artifact bias, given the concentration of ovarian-tumor predictions in the top 10
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

